Cytek Biosciences, Inc. CTKB Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 51.7%-0.1pp | 51.8%-1.6pp | 53.5%-1.0pp | 54.4%-0.5pp | 54.9%-0.5pp | |
| Free cash flow margin | -6.2%-1.9pp | -4.4%-1.4pp | -3%-8.5pp | 5.5%-3.3pp | 8.9%-2.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Inventory turnover | 2.1×0.0× | 2.1×+0.2× | 1.9×+0.1× | 1.8×0.0× | 1.8×+0.1× | |
| Liquidity | ||||||
| Current ratio | 4.7×-0.4× | 5×-0.1× | 5.2×-0.1× | 5.2×-0.4× | 5.6×-0.2× | |
| Quick ratio | 4.1×-0.3× | 4.4×-0.1× | 4.5×-0.1× | 4.5×-0.4× | 5×-0.3× | |
| Cash ratio | 0.4×0.0× | 0.4×-0.9× | 1.2×+0.2× | 1×-0.4× | 1.4×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $2.55-4.8% | $2.68-9.9% | $2.97-0.2% | $2.97+0.6% | $2.96-2.4% | |
| Valuation | ||||||
| Market capitalization | $577.27M+54.5% | $645.72M+46.3% | $441.47M+7.9% | $409.11M-20.4% | $513.67M-38.6% | |
| Enterprise value | $562.23M+93.7% | $634.18M+73.5% | $365.43M+3.9% | $351.87M-18.2% | $430.28M-42.6% | |
| Price / sales | 2.8×+0.9× | 3.2×+1.0× | 2.2×+0.2× | 2.1×-0.5× | 2.6×-1.6× | |
| Price / book | 1.8×+0.8× | 1.9×+0.7× | 1.2×+0.1× | 1.1×-0.3× | 1.4×-0.8× | |
| EV / sales | 2.8×+1.3× | 3.1×+1.3× | 1.9×+0.1× | 1.8×-0.4× | 2.2×-1.6× | |
| Free cash flow yield | -2.2%-6.9pp | -1.4%0.0pp | -1.3%-4.0pp | 2.7%-0.7pp | 3.4%+0.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Cytek Biosciences, Inc.'s profit margins?
- Cytek Biosciences, Inc. (CTKB) runs a 51.7% gross margin and a -21.5% operating margin, with a -36.2% net margin.
- Where do Cytek Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Cytek Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
